Evidence map›Paper›PMID 40751364›Full record

ArticleJournal of hepato-biliary-pancreatic sciences2025

Outcomes of Patients With Unresectable Cholangiocarcinoma After Portal Vein Embolization: A Propensity Score-Matched Analysis.

Ho Seung Lee, Tae Jun Song, Sung Hyun Cho, Gunn Huh, Dongwook Oh, Jae Min Lee, Jae Hoon Lee, Dae Wook Hwang, Dong-Wan Seo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hepato-biliary-pancreatic sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ho Seung LeeDepartment of Internal Medicine, Korea University Anam Hospital, Seoul, Korea.ORCID https://orcid.org/0009-0000-0135-7042
Tae Jun SongDepartment of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Sung Hyun ChoDepartment of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Gunn HuhDepartment of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Dongwook OhDepartment of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Jae Min LeeDepartment of Internal Medicine, Korea University Anam Hospital, Seoul, Korea.
Jae Hoon LeeDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Asan Medical Center, Seoul, Korea.
Dae Wook HwangDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Asan Medical Center, Seoul, Korea.ORCID https://orcid.org/0000-0002-1749-038X
Dong-Wan SeoDepartment of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aimed to evaluate the outcomes of patients with unresectable cholangiocarcinoma (CCA) who underwent portal vein embolization (PVE) with a focus on overall survival (OS) and the frequency of biliary drainage (BD).

methodsIn this retrospective analysis, we evaluated 255 patients with unresectable CCA; 56 patients underwent PVE but ultimately remained unresectable. Propensity score matching (PSM) was used to minimize the potential confounding factors. The primary outcome was the OS, while the secondary outcome was BD frequency.

resultsThe PVE-unresectable group showed lower OS than that in the non-PVE-unresectable group both before and after PSM (median OS: 238.5 vs. 371.0 days, p = 0.006; 238.5 vs. 483.5 days, p = 0.002, respectively). Unresectable PVE status was a predictor of worse survival both before and after PSM (hazard ratio [HR] = 2.06, p < 0.001 and HR = 2.46, p < 0.001, respectively). Chemotherapy improved survival before and after PSM (HR = 0.45, p < 0.001 and HR = 0.41, p = 0.003, respectively). The BD frequency was higher in the PVE-unresectable group than in the non-PVE-unresectable group before and after PSM (0.693 vs. 0.470 procedures per month, p = 0.010).

conclusionsPatients with unresectable CCA who underwent PVE had worse survival outcomes and required BD. Optimizing systemic therapy and BD strategies may improve the outcomes.

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaEmbolization, TherapeuticPortal VeinAgedFemaleHumansMaleMiddle AgedPropensity ScoreRetrospective StudiesSurvival RateTreatment Outcomebiliary drainagecholangiocarcinomaportal vein embolizationpropensity score matchingsurvival rate

Identifiers

PMID40751364
PMCPMC12648373

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.